The aim of this study is to assess maternal treatment outcomes to antiretroviral therapy initiated before or during pregnancy in HIV-1 infected women and associated factors in southwest Ethiopia. Hospital based retrospective cohort study was conducted from January 1st 
Introduction
The emergence of the HIV epidemic is one of the biggest public health challenges the world has ever seen in recent history. In 2011, there were 34 million people living with HIV. Among these, Sub-Saharan Africa accounts for 69% of all people living with HIV. Women account for 58% of people living with HIV in sub-Saharan Africa. In the same year, 2.5 million people became newly infected with HIV; among these 330,000 were children and 1.7 million people died from AIDS-related causes worldwide (1) .
In Ethiopia, among women aged 15-49years, HIV prevalence is 1.9 % (2). According to the 2012 world AIDS day report, 790, 000 Ethiopians were living with HIV/AIDS, 13,000 children were newly HIV infected and there were 53,831 HIV related deaths in Ethiopia [1] . During 2011, a total of 10,302 HIV positive pregnant women received ARV prophylaxis for prevention of mother to child transmission (PMTCT). However, overall coverage of PMTCT still remains as low as 24% of the expected eligible population. Mother to child transmission (MTCT) of HIV was 17% at six weeks and 30% including breast feeding (3) .
Treatment outcome of HIV infected individuals can be evaluated using virological, immunological or clinical criteria. The earliest indicator is virological followed by immunological treatment success or failure; usually clinical treatment failure becomes apparent much later (4) The immunological and clinical outcomes to HAART among HIV infected pregnant women vary according to timing of HA-ART initiation (5) . Longer duration antenatal ARV prophylaxis is more effective than shorter duration ARV prophylaxis. In research done in 10 European countries, the risk of motherto-child transmission was lower among those who initiated HAART before pregnancy than among women who initiated HAART during pregnancy, 0.25% (1 of 397) vs. 1.92% (10 of 52) respectively. The 11 women who have transmitted HIV to their children had relatively advanced HIV disease, with a median maternal CD4 cell count of 209 cells/ mm3 (64-468 cells/ mm3) (6) . In the study done in Johannesburg, South Africa, MTCT in women who started HAART before pregnancy was 0.7% (1 of 143) and 5.7% (42 of 730) in those who started HAART during pregnancy (7) .
Combination regimens are more effective than single-drug regimens in reducing perinatal transmission. A study done in Abidjan, Cote d'Ivoire, reported a significantly lower transmission rate among infants with maternal HAART (2.3%) compared to single-dose nevirapine (16.1%) (8) . In Kesho Bora study, maternal median CD4 cell counts were higher in the triple antiretroviral group than the zidovudine and single-dose nevirapine group. At enrollment, the CD4 cell counts were 336 cells/mm3 versus 339cells/ mm3, at delivery 463 /cellsmm3 versus 416 cells/ mm3, and at 6 months 479 cells/ mm3 versus 374 cells/ mm3 and 12 months 401cells/ mm3 versus 378 cells/ mm3) in the triple antiretroviral group and the zidovudine and single-dose nevirapine group respectively. The cumulative rate of HIV transmission at 6 weeks was 3.3% in the triple antiretroviral group compared with 5.0% in the zidovudine and single-dose nevirapine group (9).
Maternal plasma HIV RNA level is the best individual predictor of MTCT risk. Other risk factors include vaginal delivery, prolonged rupture of the membranes, prematurity, low CD4+ cell count, maternal symptomatic HIV disease, viral subtype, breastfeeding and host genetic factors (10).
Challenges and gaps against prevention of MTCT HIV infection include: drug resistance, drug safety, adverse effects associated with HAART, infant feeding of HIV-infected mothers, limited donor funding support, the fact that many women in resource limited settings deliver at home, many women may not seek antenatal services at health institutions, lack of male involvement in HIV testing, issues of disclosure by women of their HIV status that may prevent HIV-infected women from receiving appropriate antiretroviral interventions for both PMTCT and their own treatment and lack of comprehensive contraceptive services for HIV-infected women (11, 12) .
The CD4 cell count was significantly lower at delivery when HAART was initiated after week 14 of gestation than when it was initiated before week 14 (mean 420 cells/ mm3 vs. 484 cells/ mm3; P<0.05) in the study conducted in Denmark (13) .
In the study done in Cape Town, South Africa, advanced immunodeficiency at presentation and duration of HAART before birth were significantly associated with transmission of HIV from infected pregnant mother to her infant. All of the mothers who gave birth to HIV-positive infants had less than 8 weeks' HAART prior to delivery. There were no HIV transmissions among women who received at least 8 weeks of therapy before delivery. The MTCT of HIV rate was 5.1% (11/217) for infants whose HIV status was known in mothers who had less than eight weeks HAART prior to delivery (14) .
The risk of HIV transmission among persons with low CD4+ cell counts appears to be substantially higher than the risk among persons with higher CD4+ cell counts (15) . In the study conducted in Cameroon, Yaoundé, duration of ARV regimens more than four weeks was very important for a better reduction of MTCT risk, through increase in CD4 counts. Mothers with CD4 counts below 350cells/ mm3 had a fourfold risk of MTCT of HIV (16) .
In a pooled analysis of randomized trials from sub-Saharan Africa, children born to mothers in the advanced stages of HIV infection were at considerably higher risk of death when compared to those of mothers who were at a less advanced stage of the disease (irrespective of the child's HIV infection status), and this association was even stronger for uninfected children (17) .
Mortality was estimated in sub-Saharan countries for HIVinfected children by timing of transmission; initial time was the estimated date of acquisition of HIV-infection. Overall, 12 months post-acquisition of infection, an estimated 52% of children with peripartum infection and 26% of those with postnatal infection died (18) .
Advanced disease stage and low CD4 cell counts have been shown to be associated with a higher frequency of zidovudine resistance in the study done in Thailand (19) . In research done in Tanzania, women carrying virus variants with zidovudine selected mutations at delivery displayed a 10 fold higher median viral load compared to women without zidovudine resistance mutation at delivery (p=0.021). Nevirapine resistance was 18% and lamivudine resistance was 8%. The overall HIV transmission rate in this study cohort of 50 mother infant pairs 4-6 weeks after delivery was 14.3% and thus unexpectedly high (20) .
To enhance antiretroviral therapy initiation, antenatal care (ANC) and PMTCT have been integrated. HIV-infected women already receiving HAART are recommended to continue therapy. In addition, correction of risk factors (e.g. cigarette smoking),optimizing obstetric practice (e.g. limiting duration of membrane rupture, elective cesarean section), avoiding breast feeding and exclusive breast feeding are some among measures undertaken to improve immunological & clinical responses of HIV-infected mothers to prevent mother to child transmission (14, 21, 22) In the study done in United kingdom and Ireland, among women on HAART, 24.1% started it before pregnancy, and the median gestational age at initiation for those starting in pregnancy was 25.9 weeks (interquartile range (IQR): 22.4-28.9 weeks) (23) .
Thus, the main aim of this study was exploring the correlation of HAART initiation time and the treatment outcomes of mothers, and identifying factors affecting maternal treatment outcomes.
Method and Participants
The study was conducted at Jimma University specialized hospital (JUSH), which is one of the oldest public hospitals in the country. Geographically, it is located in Jimma city 352km southwest of Addis Ababa. It provides service for approximately 9000 inpatients and 80,000 outpatients a year coming to this hospital from the catchment population of about 15,000 million people (27).
In Women who started HAART before or during pregnancy and whose baseline and current CD4+ cell counts were known, baseline and current WHO clinical stages were known, having legible and complete record card were included in the study. However, HIV infected women without complete CD4+ cell counts of their follow up period, who were on non-HAART or OIs prophylaxis were excluded from the study.
The independent variables or factors that could affect the outcome variables include age of the women, HIV status prior to pregnancy, HAART initiation time, duration on HAART, Baseline CD4+ lymphocyte count, baseline WHO clinical stage, history of AIDS defining events, mode of delivery, number of pregnancy, while the dependent variables is maternal treatment outcomes which was categorized as good and poor as defined below in the operational definition.
Data were collected using data collection tool adapted from similar literatures and commented by experts. The data collection tool includes socio-demographic characteristics and clinical characteristics of the pregnant women. Data collection was done by three BSc degree holder nurses.
To ensure data quality, training was given by principal investigator for data collectors and supervisor to have common understanding of the objectives of the study and data collection tool. Pre-test was done on ten HIV infected pregnant women record cards before the actual data collection. The result was not included in the main study; however, modification was made on the data collection tool accordingly. Anything which was unclear or ambiguous was corrected on the next day. Before data analysis, data cleaning was also performed in order to ensure the quality.
Data were then checked, entered, coded, and analyzed using SPSS for windows version 16.0 statistical software package (Chicago: SPSS Inc., 2007). For descriptive statistics, results were expressed in terms of percentages in tables and figures. Binary logistic regression analysis was performed to see the association between each factor with maternal clinical and immunological outcomes. Independent predictors of maternal treatment outcome were identified by using backward multivariate logistic regression analysis. A p-value of <0.05 was considered statistically significant.
The research proposal was approved by the Jimma University IRB. A formal letter for permission and support was written to the respective hospital administration and subsequently official permission was obtained from the responsible hospital administration. Patients' names were not written on the data collection tool for keeping the confidentiality of the information obtained. The patient record cards were returned back to the record office.
The investigators operationally defined the following terms for the current study purpose as:
Good Immunological outcome: change in CD4+ lymphocyte count from start date of HAART to delivery. If there is an increase in CD4+ lymphocyte count; it is termed as good immunological outcome. But, if there is a decrease or constant in CD4+ lymphocyte count; it is termed as poor immunological outcome. Study participants were classified according to timing of first HAART initiation. Women will be classified as initiating HAART before or during first pregnancy while in care if they started first HAART ≥30 days before estimated date of conception (DOC), <30 days before DOC respectively. The 30-day window before date of conception was used due to uncertainty of the estimated date of conception as determined by last menstrual period (28) (29) (30) (31) . Women who started HAART during pregnancy was presumed to start HAART for prevention of mother-to-child HIV transmission (PMTCT) and not for maternal health if they had no previous opportunistic infections, had nadir CD4+ lymphocyte count >350 cells/mm3.
HAART was defined as regimens of ≥7 day's duration that contained two nucleoside reverse-transcriptase inhibitors (NRTI) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI), or a third NRTI. Non-HAART antiretroviral therapy (ART) included mono-or dual-NRTI therapy.
Maternal treatment outcome: it is assessed using maternal clinical outcome and maternal immunological outcome. Both maternal clinical and immunological outcome were grouped as good or poor.
Results

Factors affecting maternal immunological outcome
Among 202 pregnant women, 33 (16.3 %) had poor immunological outcome (Fig 1) . (Table II) .
Factors affecting maternal clinical outcome
Of 202 HIV positive pregnant women, 60 (29.7 %) had poor clinical outcome (Figure 2 ). In unadjusted logistic regression analysis, unknown HIV status prior to pregnancy (COR=3.350, (Table III) . (Table IV) .
Discussions
In the current study, WHO clinical stages before HAART initiation accounts 108 (53.5%) for stage I & II, 65 (32.2%) for stage III and 29 (14.45%) for stage IV. This finding is comparable with the study done in Cape Town, South Africa in 2010 G.C., baseline WHO clinical stage III which accounts 78 (34%) but different with baseline WHO clinical stage I and II that account 179 (79%) and WHO clinical stage IV which accounts 8 (3%). The possible reason can be difference in time of visiting health institutions, which in turn is influenced by fear of stigma and discrimination (14) .
The median CD4 count before HAART initiation in the current study, 210 cells/ mm3, was greater than the one reported from Johannesburg, South Africa, which was 160 cells/ mm3 and Cape Town, South Africa, which was 134 cells/ mm3. The possible reasons for these differences can be, in Johannes-burg, most of the pregnant women had baseline CD4 count <200 (76 %) and in Cape Town, between the range of 84 and 168. But, in Cameroon, Yaoundé, the median baseline CD4 (368 cells/ mm3) was greater than the current study finding. The possible reason might be the IQR, which was between 310-450cells/mm3 that is greater than the IQR 111.75 -324.75 of the current study (7, 14, 16) .
Unknown HIV status prior to pregnancy which accounts 60 (29.7%) is less than the study done in Angola, 55 (52.9%) in 2012. The possible reason can be difference in the sample size. In this study, 87 (43.6%) pregnant women started HA-ART during pregnancy but majority of women (85.2%) started HAART during pregnancy in Johannesburg, South Africa. The possible reason for the difference can be most of the study participant in Johannesburg (76 %), South Africa had CD4 count less than 200 cells/mm3 before initiation of HAART. The time at which HAART initiated in Denmark was 77.4% and 22.6% before and during pregnancy respectively. The difference can be due to prior pregnancy HIV status screening behavior in Denmark. Pregnant women who delivered their birth through CS account 11(7.4%) which is comparable with the study done in Cameroon, Yaoundé, 36 (8.6%). The mean duration of treatment in those who initiated HAART during pregnancy was 4.07 months and 32.03 months for those who initiated HAART before pregnancy. This is greater than 10.7 weeks and 93.4 weeks of total HAART duration during and before pregnancy respectively, in Johannesburg, South Africa. The possible reason for this difference can be time of first visit of health institution, specifically ANC clinic (7, 16, 24) .
In this study, unknown HIV status prior to pregnancy had association (P = 0.009) with maternal immunological outcome. It was also independent predictors of immunological outcome (AOR = 0.158, 95% CI = 0.041 -0.546, P = 0.007). This finding was not similar with the study done in Nashville, Tennessee, in 2009(5). The possible reason can be, HIV status prior to pregnancy was not assessed in the study done in Nashville, Tennessee. Knowing HIV status can have an impact on effective HAART utilization, which results in increasing survival, better support for childbearing provided to HIV-infected women and early identification and testing, women at high risk of infection.
HIV status prior to pregnancy, WHO clinical stage before HA-ART initiation, CD4 lymphocyte count before HAART initiation, HAART initiation before pregnancy and duration of treatment with HAART were associated with maternal clinical outcome in binary logistic regression analysis (p < 0.05). However, from the above variables, independent predictors of clinical treatment outcome were time of HAART initiation, WHO clinical stage before HAART initiation and duration of treatment with HAART. From this we can understand that women who started HAART before pregnancy, those at lower WHO clinical stage (like I and II) and those who have been on HAART for longer period of time showed good clinical outcomes, which could be explained by absence of opportunistic infection or clinical improvement.
HAART initiation during pregnancy is 0.349 less likely to have good clinical outcome compared to HAART initiation before pregnancy (AOR = 0.349, 95% CI = (0.157 -0.776), P= 0.010). Time of HAART initiation has impact in mother to child transmission of HIV. Different studies from South Africa, United Kingdom and Europe have showed similar reports as risk of MTCT of HIV increases markedly in those women who started HAART during pregnancy compared to those who started before pregnancy. Even though, it was not the objective of this study, there was MTCT of HIV in women who started HAART during pregnancy (2.3%) while no MTCT of HIV from those who initiated their HAART before pregnancy. The total treatment duration with HAART was one month in those women who transmitted HIV to their infants. The possible reason could be due to an increased risk of intra-uterus transmission before initiation of treatment. Of course, timing of HAART is not the only factor exhibiting MTCT of HIV (6, 7, 24) .
WHO clinical stage III before HAART initiation was 7.673 times more likely to have poor clinical outcomes compared to WHO clinical stage I (AOR = 7.673, 95 % CI = 1.640 -35.892, P= 0.010). Women who were with one or more opportunistic infection were less likely to achieve expected treatment outcome. The duration of treatment with HAART between 13-18 months was 0.193 less likely to have good clinical outcome compared to the duration of treatment with HAART >18 months (AOR = 0.193, 95% CI =0.056 -0.669, P= 0.010). The longer the women on HAART, the better the clinical outcome. However, the independent predictors of maternal clinical outcome were different from the study done in Nashville, Tennessee (5). The possible reason can be difference in sample size, initial WHO stage during HAART initiation and treatment duration with HAART.
Even though effort has been made to achieve the objectives of this study, there were certain limitations like low sample size, lack of information about patients' adherence because of the nature of the study design, lack of maternal viral load result and lack of actual economic status of the women, poor documentations of the women follow up profile and being retrospective study.
In conclusion, Women who started HAART before pregnancy had good clinical outcome compared to those who started during pregnancy. The independent predictors of maternal immunological outcome were HIV status prior to pregnancy and CD4 count before initiation of HAART. The independent predictors of maternal clinical outcome were time of ART initiation, WHO clinical stage before initiation of HAART and duration of treatment with HAART. Women in the reproductive age group should be encouraged to know their HIV status before pregnancy and should be encouraged to start HAART early if they fulfill the eligibility criteria.
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